



28 July 2022

REPORT FOR THE QUARTER ENDED 30 JUNE 2022

Bioxyne Limited (ASX Code: BXN) (Bioxyne or the Company) is pleased to report on its activities for the quarter ended 30 June 2022.

Highlights

- **Positive operating cash flow for the quarter and FY2022**
- **Cash balance remains at ~\$2 million**
- **Revenues 33% down for quarter but +14.5% up for FY2022**
- **Further order of ColosNZ PRO for SE Asia received**

Results

Sales revenue (unaudited) for year ended 30 June 2022 was \$2.4 million (2021: \$2.1 million), +14% up on the previous year.

Wholesale sales of the Company's patented strain of probiotics *Lactobacillus fermentum* PCC® remains firm with revenue 6.6% up on the prior year at \$1.9m. The Group is looking to relaunch its probiotic *Progastrim* for its direct sales and online business, with enhanced stability, given benefits of probiotics being shown in post COVID recovery, by various clinical studies. The direct sales business in Indonesia is recovering post COVID and the Company continues to seek opportunities to expand distribution in other Asian countries for its PCC® formulated product.

The unaudited result for year is a loss of approximately \$239k (2021: audited loss \$496k) after taking up a non-cash impairment charge of \$133k (2021:\$224k) against inventory held in Asian countries where COVID has slowed sales and pushed product beyond expiry date.

The Company achieved a positive Operating Cashflow of \$71k for the quarter and a positive cashflow of \$429k for the financial year 2022. Cash at the end of the quarter \$2.16m.



Operations

Wholesale sales of the Company's patented strain of probiotics, *Lactobacillus fermentum* PCC® continues to be firm. There is now a growing body of literature in support of probiotics in assisting recovery post COVID. Following growing enquiry Bioxyne is working on a relaunch of its proprietary TGA registered consumer probiotic *Progastrim* for online and direct sales.

The Group has received a further order of ColosNZ PRO from South East Asia and expect growing traction in this immune support product. A successful trial has also indicated that the Company's proprietary probiotic *Lactobacillus Fermentum* PCC® can be incorporated into this product through nano encapsulation giving the product further efficacy in building immune system support.

The Bioxyne product suite comprises:

***Lactobacillus Fermentum* PCC®** - patented strain of probiotics wholesale to contract manufacturers for use with their clients' consumer probiotics

Progastrim™ (PCC®) - clinically tested proprietary patented probiotic, for general gut health and immune support

Mymana™ – colostrum and fortified milk formula for nutrition and immune support

ColosNZ PRO™ – enhanced colostrum and fortified milk formula for nutrition and immune support

Col-Coffee™ - three in one instant coffee mix with colostrum

BK18™ – NZ dairy-based formula with probiotics and vitamins for general health and immune support

Allura™ – weight management and beauty drink for women

Mustang™ – weight management and vitality shake for men

New business opportunities focus

The Company is actively seeking acquisitions of businesses or products to broaden its operating base which would build shareholder value.

Corporate

Payments to related parties and their associates during the quarter of \$65,000 comprise director and non-executive director salaries, fees and superannuation.

Mr. Patrick Ford, a long serving non-executive director of the Company retired from the board at 30 June 2022. Mr. Guy Robertson was appointed executive director of the Company on 30 June 2022.



This quarterly activity report has been approved by the Board.

For more information, please contact:

Tony Ho, Chairman, , Bioxyne Limited - +61 417 345 839 email tony.ho@bioxyne.com

Guy Robertson, Executive Director/ CFO +61 407 983 270 email guy.robertson@bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian health and wellness products company (incorporated in 2000) with a focus on clinically effective health and wellness products particularly in the gut and immune health areas.

Bioxyne is in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* VRI-003 (PCC®), and through its direct sales business trading as Bioxyne International, the Company has developed a range of functional food products containing ingredients sourced primarily from New Zealand.

Bioxyne's probiotic business is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne has a distribution agreement for PCC® with Nu-Skin Enterprises (USA) a successful worldwide **direct selling** company.

For more information on Bioxyne, please visit www.bioxyne.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bioxyne Limited

ABN

97 084 464 193

Quarter ended ("current quarter")

30 June 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	753	2,890
1.2 Payments for		
(a) research and development		
(b) product manufacturing and operating costs	(423)	(1,387)
(c) advertising and marketing		
(d) leased assets		
(e) staff costs (including directors fees)	(73)	(352)
(f) administration and corporate costs	(212)	(760)
1.3 Dividends received (see note 3)		
1.4 Interest received	3	15
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	23	23
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	71	429
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities		

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options		
3.4 Transaction costs related to issues of equity securities or convertible debt securities		
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities		

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	1,970	1,602
4.2 Net cash from / (used in) operating activities (item 1.9 above)	71	429
4.3 Net cash from / (used in) investing activities (item 2.6 above)		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)		
4.5	Effect of movement in exchange rates on cash held	127	137
4.6	Cash and cash equivalents at end of period	2,168	2,168

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,570	1,337
5.2	Call deposits	598	633
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,168	1,970

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

65

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

- 7.1 Loan facilities
- 7.2 Credit standby arrangements
- 7.3 Other (please specify)
- 7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

7.5 Unused financing facilities available at quarter end

- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

--

8. Estimated cash available for future operating activities**\$A'000**

8.1	Net cash from / (used in) operating activities (Item 1.9)	71
8.2	Cash and cash equivalents at quarter end (Item 4.6)	2,168
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	2,168
8.5	Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

- 8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 July 2022.....

Authorised by: ..The Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.